NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 87 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $303,000 | -79.7% | 112,784 | -67.2% | 0.00% | -100.0% |
| Q1 2022 | $1,490,000 | +221.1% | 343,361 | +283.4% | 0.00% | – |
| Q4 2021 | $464,000 | -73.7% | 89,557 | -68.9% | 0.00% | -100.0% |
| Q3 2021 | $1,766,000 | +358.7% | 287,649 | +655.0% | 0.00% | – |
| Q2 2021 | $385,000 | – | 38,101 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $43,842,000 | 30.79% |
| Madrona Venture Group, LLC | 6,020,770 | $16,196,000 | 7.52% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $3,647,000 | 3.82% |
| Ally Bridge Group (NY) LLC | 1,080,566 | $2,907,000 | 2.65% |
| Tikvah Management LLC | 1,488,895 | $4,005,000 | 1.73% |
| ArchPoint Investors | 1,449,551 | $3,899,000 | 1.54% |
| Perceptive Advisors | 9,111,151 | $24,508,000 | 0.77% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $5,380,000 | 0.63% |
| CROWN ADVISORS MANAGEMENT, INC. | 250,000 | $672,000 | 0.62% |
| Affinity Asset Advisors, LLC | 466,607 | $1,255,000 | 0.53% |